Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation.

ABSTRACT:

Background

Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed doses, which raises concerns of its effectiveness on larger patients. Data from randomized trials are limited on the safety and efficacy of DOACs in morbidly obese individuals with atrial fibrillation (AF).

Methods

We analyzed a cohort of obese (≥ 120 kg) and morbidly obese (BMI > 40 kg/m²) patients from the Veterans Health Administration system with AF who initiated apixaban, rivaroxaban, dabigatran, or warfarin between years 2012 and 2018. We used inverse probability of treatment weighting (IPTW) and Cox proportional hazards regression models to evaluate the relative hazard of death, myocardial infarction (MI), ischemic stroke, heart failure (HF), and bleeding events between

SUBMITTER: Briasoulis A 

PROVIDER: S-EPMC8382577 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature